Brought to you by 
Oxagen raises $59.8mm via Series B round
01 Dec 2009
Executive Summary
Drug discovery and development company Oxagen Ltd. has raised £31.6mm ($59.8mm) in its Series B venture round, an offering of Series B preferred shares. The financing was led by MPM Capital. Also participating were other new investors Bessemer Venture Partners, IBT, and Red Abbey along with existing backers SV Life Sciences, Advent Ventures, 3i, Abingworth, and the Wellcome Trust.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oxagen raises $59.8mm via Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice